Mabwell (Shanghai) Bioscience (SHA:688062, HKG:2493) said China's National Medical Products Administration approved a clinical trial application for its investigational drug 9MW5211 to treat multiple sclerosis, according to a Thursday Hong Kong bourse filing.
9MW5211 is a proprietary antibody designed to selectively target pathogenic immune cells involved in autoimmune diseases, the filing said.